In patients given a diagnosis of chronic spontaneous urticaria (CSU), there are no obvious
external triggers, and the factors that initiate the clinical symptoms of wheal, flare, and itch …

IgE is central to the pathophysiology of allergic asthma. Omalizumab, a humanized anti-IgE
mAb, specifically binds free IgE and interrupts the allergic cascade by preventing binding of …

Abstract Development of monoclonal antibodies (mAbs) and their functional derivatives
represents a growing segment of the development pipeline in the pharmaceutical industry …

Current asthma therapy is based on the use of adrenergic bronchodilator and anti-
inflammatory drugs the specificity, efficacy, duration of action, and safety of which have been …

We previously reported the French real-life experience of 1 year of add-on treatment with
omalizumab in 101 severe allergic asthmatic children (6–18 years), 92 of whom were still …

About 20 years after the identification of immunoglobulin E (IgE) and its key role in allergic
hypersensitivity reactions against normally harmless substances, scientists have started …

Omalizumab, a human immunoglobulin (Ig) G1 antibody against IgE, is a therapeutic agent
for bronchial asthma. The Global Initiative for Asthma guidelines indicate that the use of …

Elevated serum levels of both total and allergen-specific immunoglobulin E (IgE) correlate
with atopic diseases such as allergic rhinitis and allergic asthma. Neutralization of IgE by …

Abstract Background Omalizumab (anti-IgE monoclonal antibody) is an approved add-on
therapy for Japanese patients with severe allergic asthma. As directed by the Ministry of …

Background Omalizumab, a humanized anti‐I g E monoclonal antibody, has demonstrated
efficacy in patients with severe allergic asthma. However, treatment responses vary widely …